Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Septerna, Inc.NASDAQ: SEPN

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables turns positive

Q3 FY2026 accounts payables was $2.8M, compared with -$2.85M a year earlier. Trailing-twelve-month accounts payables was $3.07M. Over 3 fiscal years it compounded at +56.4% a year.

Context

  • Accounts payables amounted to 14.4% of revenue in FY2025, down 52.9 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $2.8M or moves back toward the trailing-twelve-month quarterly average of $768.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.8M+180.1% QoQ
Last fiscal yearDec 2025
$6.6M+813.3% YoY
LTMSep 2026
$3.07M+363.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+198.1%——
1 year+813.3%——
3-year CAGR+56.4%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
6.6M USD
Year-over-year change
+813.3%
3-year CAGR
+56.4%

Accounts Payables vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 accounts payables of $3.07M is the 3rd largest of the 7 companies compared; the peer median is $211.6K.
  • Its year-over-year change of +363.6% is the 2nd highest of 6, against a peer median of -21.9%.
  • Accounts payables amounts to 3.2% of revenue for SEPN, versus a peer median of 6.7%.
SEPN Competitors Peer median
Accounts Payables for SEPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRAKailera Therapeutics, Inc.FY2025$4.69M ———
BMEABiomea Fusion, Inc.LTM Mar 2026$3.1M -201.8%——
SEPNSepterna, Inc.LTM Sep 2026$3.07M +363.6%+56.4%3.2%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$3.05M +420.9%——
VTVTvTv Therapeutics Inc.LTM Mar 2026$1.96M -21.9%—5.3%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.61M +159.9%-80.7%8.0%
GPCRStructure Therapeutics Inc.LTM Jun 2026$1.18M -117.3%+30.3%—
Peer median (excluding SEPN) $211.6K-21.9%-25.2%6.7%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.68M)4.18M(71.8M)(48.88M)
Depreciation & Amortization577K848K1.4M1.6M
Deferred Income Tax0491K(491K)0
Stock-Based Compensation1.52M1.62M3.15M8.48M
Change in Working Capital1.75M926K248K162.78M
Accounts Receivables0(151K)(20K)(10.19M)
Inventory0000
Accounts Payables1.73M(653K)723K6.6M
Other Working Capital20K1.73M(455K)166.36M
Other Non-Cash Items530K(46.79M)18K(13.79M)
Operating Cash Flow(23.3M)(38.72M)(67.47M)110.19M
Capital Expenditures(1.29M)(2.88M)(2.1M)(518K)
Acquisitions (Net)00012.5M
Purchases of Investments00(213.39M)(450.95M)
Sales of Investments0032.27M209.62M
Other Investing Activities025M22.63M0
Investing Cash Flow(1.29M)22.12M(160.6M)(229.35M)
Debt Repayment0000
Common Stock Issued82K0302.79M1.69M
Common Stock Repurchased0(1K)(1K)(1K)
Dividends Paid0000
Other Financing Activities0052K0
Financing Cash Flow30.05M74.52M377.78M1.69M
Effect of Forex Changes0000
Net Change in Cash5.46M57.92M149.71M(117.47M)
Free Cash Flow(24.59M)(41.6M)(69.57M)109.67M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.